The global North America point-of-care molecular testing for infectious diseases market is expected to reach US$ 44.59 billion in 2031 from US$ 19.21 billion in 2023. The market is estimated to grow with a CAGR of 11.1% from 2023 to 2031.
Download Sample PDF Copy: https://www.businessmarketinsights.com/sample/BMIRE00030329
Leading Companies in the North America Point-of-Care Molecular Testing Market:
Cue Health
BD (Becton, Dickinson and Company)
Abbott Laboratories
Roche Diagnostics
Cephe... moreThe global North America point-of-care molecular testing for infectious diseases market is expected to reach US$ 44.59 billion in 2031 from US$ 19.21 billion in 2023. The market is estimated to grow with a CAGR of 11.1% from 2023 to 2031.
Download Sample PDF Copy: https://www.businessmarketinsights.com/sample/BMIRE00030329
Leading Companies in the North America Point-of-Care Molecular Testing Market:
Cue Health
BD (Becton, Dickinson and Company)
Abbott Laboratories
Roche Diagnostics
Cepheid
BioMérieux
Quidel Corporation
Danaher Corporation
Hologic, Inc.
Thermo Fisher Scientific, Inc.
Market Segmentation (2023–2031 Forecast)
By Disease:
Respiratory Infections: Dominated 2023 revenue, driven by COVID-19, flu, and RSV testing demand.
HIV/STDs: Emerging growth due to at-home testing trends and privacy-focused solutions.
By Technology:
Lateral Flow Assays: Largest share (2023), favored for speed and affordability.
Molecular Diagnostics (PCR/INAAT): Fastest-growing segment, enabled by portable PCR devices.
By Sample Type:
Blood Samples: Leading segment (2023), critical for HIV/hepatitis testing.
Nasal/Oropharyngeal Swabs: Gaining traction with respiratory pathogen multiplex kits.
By End User:
Hospitals & Clinics: Largest share (2023), driven by high patient throughput.
Home Care: Accelerating growth due to telehealth integration and self-testing kits.
Regional Dynamics: U.S. Leads, Canada Follows
United States: Accounts for ~85% of the regional market, supported by aging demographics, federal funding (e.g., BARDA contracts), and FDA fast-track approvals.
Canada: Rising investments in rural healthcare access and partnerships (e.g., 19 to Zero’s BD Veritor pilot) bolster growth.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage By: Diseases (HIV Testing, Influenza Testing, Sexually Transmitted Diseases Testing, Hepatitis C Virus Testing, Tropical Diseases Testing, Respiratory Infection Testing, Hospital Acquired Infections, Strep, Others), Technology (Lateral Flow Assay, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Solid Phase, Others), Prescription Testing (Prescription Based Testing, OTC Testing), Sample (Blood Sample, Urine Sample, Nasal and Oropharyngeal Swabs Sample, Others), End User (Hospitals and Clinics, Home Care Settings, Ambulatory and Urgent Care Facilities, Nursing Home and Assisted Living Facilities, Research Laboratories, Diagnostics Centers), Distribution Channel (E-Com Platforms, Retail Channel and Pharmacies, Others), and Country - Download Free PDF Brochure
Enquiry Form
